FRATES JAMES M (CIK 1235598) reported 9 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-09-14). Recent activity: Sell AMLX (9,768 shares), Sell AMLX (1,042 shares), Buy AMLX (22,807 shares), Buy AMLX (95,990 shares), Sell AMLX (7,909 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Sell | 9,768 | $315,195 |
| 2026-09-14 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Sell | 1,042 | $34,626 |
| 2026-08-20 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Buy | 22,807 | $0 |
| 2026-03-09 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Buy | 95,990 | $0 |
| 2026-03-04 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Sell | 7,909 | $114,839 |
| 2026-02-04 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Sell | 3,557 | $52,110 |
| 2026-01-08 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Sell | 3,326 | $36,952 |
| 2025-10-02 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Financial Officer | Sell | 10,558 | $154,675 |
| 2025-07-31 | Sage Therapeutics, Inc. (SAGE) | Director | Sell | 2,845 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-09-14